NetraMark Delivers Transformational Quarter Of Execution

Contract Backlog Expands to C$2.5M, FDA CPIM Completed, Nature Portfolio Study Accepted, Major Channel Partner Onboarding, and CAMH Research Award SecuredTORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting significant progre ...